Developing a new medicine that can successfully treat patients and combat drug resistance ideally requires at least two drugs in combination, each with a different mechanism of action or different mechanism of resistance. At any one time, there are 14 compounds in MMV’s translational portfolio, and the resulting number of new combinations to sort through and prioritize is potentially over 100. Selecting the optimal combination is a complex scientific challenge.
MMV and partners have developed and implemented a series of platforms to gather data to feed into a tool that enables every compound pair to be compared in a similar manner. This allows unbiased prioritization of optimal drug combinations for further research. We call this the Combo tool.
Read more about the Combo tool in an interview with Dr Nicole Andenmatten, Project Manager, Translational Science, MMV